Bayer to Battle Pfizer, U.S. in Selling a Cholesterol Drug to Consumers

(Bloomberg) -- Bayer AG plans to succeed where Merck
& Co. and Bristol-Myers Squibb Co. failed: Selling U.S. consumers
a cholesterol drug without a prescription.

The company that gave the world aspirin 100 years ago is
talking to U.S. regulators about a low-dose version of Bristol-
Myers's Pravachol, a member of the statin drug class that includes
Pfizer Inc.'s Lipitor. At stake is a slice of the more than $22
billion spent worldwide on cholesterol-lowering pills.


Read more at Bloomberg Exclusive News